Search results
GSK shares fall 9% in wake of Zantac court ruling
Pharmaceutical Technology via Yahoo Finance· 3 days agoMonday saw a 9% drop in GlaxoSmithKline’s (GSK) share price on the London Stock Exchange (LSE), following a Delaware judge’s ruling...discontinued...
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
CNBC· 4 days agoCompany logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain...
Business | Jun 8th 2024 Edition
The Economist· 15 hours agoIndia’s stockmarket, which became the world’s fourth-largest earlier this year, swung wildly in the wake of a surprise election result that saw Narendra...
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 5 days agoProgression-free survival (PFS) was significantly higher with belantamab mafodotin (belamaf;...
Docs Endorsing Products on X May Not Disclose Company Ties
Medscape· 23 hours agoNearly one in three physicians endorsing drugs and devices on the social media platform X did not...
Novartis sues Maryland over law prohibiting restrictions on 340B drugs
Becker’s Hospital Review· 7 days ago"Novartis sues Maryland over new law restricting 340B drug pricing program, citing conflict with federal law and potential harm to constitutional rights."
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 hours agoParacetamol Market size is set to grow by USD 929.4 million from 2024-2028, Significant use of paracetamol as API in large number of OTC drugs to boost the market growth, Technavio PR Newswire NEW YORK, June 6, 2024 NEW YORK, June 6, 2024 /PRNewswire
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 6 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
Head-To-Head Survey: Ionis Pharmaceuticals (NASDAQ:IONS) versus Nurix Therapeutics (NASDAQ:NRIX)
ETF DAILY NEWS· 2 days agoNurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoRNAi Therapeutics and Technology Market Worth USD 5.36 Billion by 2031 at 16.6% CAGR- Exclusive Report by InsightAce Analytic Pvt. Ltd. PR Newswire JERSEY CITY, N.J., June 4, 2024 JERSEY CITY, N.J., June 4, 2024 /PRNewswire/ -- InsightAce Analytic
